Organisation paid for research Program year 2025 Source: CMS Open Payments

Caprock Gastro Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,124,059

324 payments

Through program year 2025, Caprock Gastro Research LLC is reported as receiving $1,124,059 in research payments, across 324 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $296,347 21
2024 Research $82,804 13
2023 Research $87,014 16
2022 Research $191,686 105
2021 Research $412,498 113
2020 Research $53,711 56

Breakdown

Who paid Research payments · program years 2020–2025
  1. AbbVie, Inc. $520,908 88 payments
  2. Eli Lilly and Company $450,036 17 payments
  3. Janssen Research & Development, LLC $78,293 23 payments
  4. Esperion Therapeutics, Inc. $74,822 196 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $304,826 5 payments
  2. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) $249,872 9 payments
  3. A Phase 3, Multicenter, Open Label, Long Term Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease $98,745 7 payments
  4. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $74,822 196 payments
  5. A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis $62,130 21 payments
  6. A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 $45,320 9 payments
  7. A Phase 3 Multicenter Open Label Long Term Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease $43,506 2 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies $34,330 6 payments
  9. A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 $27,433 15 payments
  10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy $25,986 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record